Asset
Berotralstat
BioCryst Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03136237 | phase1 | completed | 2017-02-17 | 2017-08-15 | BioCryst Pharmaceuticals | A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions |
| NCT03472040 | phase2_3 | completed | 2018-02-16 | 2022-04-27 | BioCryst Pharmaceuticals | A Long Term Safety Study of BCX7353 in Hereditary Angioedema |
| NCT03202784 | phase1 | completed | 2017-02-27 | 2017-08-01 | BioCryst Pharmaceuticals | A Relative Bioavailability Study of Two Formulations of BCX7353 |
| NCT02819102 | phase1 | completed | 2016-03-01 | 2016-06-01 | BioCryst Pharmaceuticals | An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates |
| NCT02870972 | phase2 | completed | 2016-08-01 | 2017-08-01 | BioCryst Pharmaceuticals | Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema |
FDA applications (0)
This company has no applications containing this asset.